Atrial natriuretic peptide (ANP) is a hormone produced by the heart that helps regulate blood pressure, fluid balance, and sodium levels throughout the body. Its discovery in the early 1980s overturned the long-standing assumption that the heart was purely a mechanical pump, revealing it as an endocrine organ capable of secreting hormones into the bloodstream.1PubMed. Thirty years of research on atrial natriuretic factor: historical background and emerging concepts ANP’s reach extends well beyond simple fluid management, though, touching immunity, fat metabolism, fetal development, and the way modern heart failure drugs work.
How the Heart Decides to Release ANP
ANP is stored in granules inside muscle cells of the heart’s upper chambers, the atria. The primary trigger for its release is mechanical stretch. When blood volume rises and atrial walls are pulled taut, that physical tension prompts the cells to dump stored ANP into the circulation.2PubMed. Pressor hormones regulate atrial-stretch-induced release of atrial natriuretic peptide in the pithed rat The response is dose-dependent: more stretch means more hormone released. In cultured atrial cells, applying tension increased the genetic instructions for making ANP by roughly ninefold compared to unstretched cells, showing that the heart doesn’t just release what it has on hand but ramps up production when demand is high.3PubMed. Stretch-dependent regulation of atrial peptide synthesis and secretion in cultured atrial cardiocytes
This stretch-sensing mechanism is elegant because it responds directly to the problem ANP is meant to fix. Too much fluid in the bloodstream increases the blood returning to the heart, stretching the atria, and the stretched atria respond by releasing the very hormone that tells the kidneys to shed salt and water. It’s a built-in feedback loop.
What ANP Does in the Kidneys
The kidneys are ANP’s most important target organ. Once ANP reaches the kidney, it promotes sodium excretion (natriuresis) and water excretion (diuresis) through two complementary routes: it raises the rate at which blood is filtered through the kidney’s tiny filtration units, and it reduces how much of that filtered sodium and water gets reabsorbed back into the bloodstream.4Kidney International. The renal action of atrial natriuretic peptide during control of glomerular filtration The net effect is that you produce more urine with a higher salt content, which lowers blood volume and, with it, blood pressure.
ANP belongs to a family of natriuretic peptides whose collective job is to oppose the body’s main salt-retaining system, the renin-angiotensin-aldosterone system (RAAS).5PubMed Central. Protective Renal Effects of Atrial Natriuretic Peptide: Where Are We Now? Where RAAS tells the kidneys to hold onto salt and water, ANP tells them to let it go. That tug-of-war keeps your fluid balance within a narrow, healthy range.
How ANP Lowers Blood Pressure Beyond the Kidneys
ANP doesn’t rely on the kidneys alone. It reduces plasma volume by at least three mechanisms: increased renal excretion, vasodilation, and increased vascular permeability.6JCI Insight. Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume When ANP relaxes the smooth muscle lining blood vessel walls, vessels widen and blood pressure drops. At the same time, ANP makes the walls of tiny blood vessels slightly more permeable, allowing some fluid to shift out of the bloodstream and into surrounding tissues, which further reduces circulating volume.
ANP also dials down the nervous system’s contribution to blood pressure. It reduces the activity of sympathetic nerves that supply the kidneys, which relaxes the kidney’s own blood vessels and lowers the signals that would otherwise tell the body to retain salt. In animal studies, ANP infusion caused measurable drops in renal sympathetic nerve activity along with a slowing of the heart rate.7PubMed. Role of supraspinal vasopressin neurones in the effects of atrial natriuretic peptide on sympathetic nerve activity This effect appears to involve a neural pathway running through the hypothalamus, the brain region that coordinates many hormonal and autonomic responses.
Fighting the Salt-Retaining System
The antagonism between ANP and the renin-angiotensin-aldosterone system deserves its own look because it affects so many downstream processes. ANP suppresses renin, the enzyme that kicks off the RAAS cascade. It also suppresses aldosterone, the hormone that tells the kidneys to reabsorb sodium, and vasopressin (also called antidiuretic hormone), which tells the kidneys to reabsorb water. ANP even reduces thirst.8PubMed. Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists Each of those actions individually lowers blood pressure, blood volume, or both; together, they form a coordinated counter-program to salt and water retention.
The suppression of aldosterone appears to last longer than the suppression of renin. In anesthetized animals given an ANP infusion, renin activity dropped at the 30-minute mark but recovered afterward, while aldosterone remained suppressed well into the recovery period.9PubMed. The effects of atrial natriuretic peptide on renal function and the renin-aldosterone system in anesthetized rabbits In practice, that means ANP’s influence on aldosterone may outlast its influence on other parts of the system, keeping sodium excretion elevated even after ANP itself is cleared from the blood.
ANP’s inhibition of vasopressin is part of this same anti-retention campaign. In laboratory tissue preparations, ANP inhibited vasopressin release through a slowly activated mechanism, with the strongest effect appearing to originate in the hypothalamus.10PubMed. In vitro evidence for an inhibitory effect of atrial natriuretic peptide on vasopressin release Less vasopressin means the kidneys reclaim less water, so you produce more dilute urine and shed more fluid.
The Signaling Chain Inside Cells
When ANP reaches a target cell, it binds to a receptor on the cell surface known as natriuretic peptide receptor A (NPRA). This receptor has a built-in enzyme that, once activated, produces a signaling molecule called cyclic GMP (cGMP) inside the cell.11PubMed Central. Molecular Signaling Mechanisms and Function of Natriuretic Peptide Receptor-A in the Pathophysiology of Cardiovascular Homeostasis cGMP then flips further switches, activating an enzyme called protein kinase G (PKG), which carries out the actual work of relaxing smooth muscle, adjusting kidney function, and curbing cell growth.12PubMed. Atrial natriuretic peptide induces natriuretic peptide receptor-cGMP-dependent protein kinase interaction This chain of events matters clinically because it means anything that interferes with cGMP production or breakdown can blunt ANP’s protective effects.
ANP is cleared from the bloodstream by a combination of enzymes and a separate receptor. An enzyme called neprilysin breaks ANP down, and a different receptor (natriuretic peptide receptor C) pulls ANP out of circulation by internalizing and degrading it. Insulin-degrading enzyme also plays a role.13PubMed Central. Natriuretic peptide metabolism, clearance and degradation Understanding these clearance pathways became directly relevant to drug development, as we’ll see below.
Anti-Inflammatory and Immune Effects
ANP receptors are found on immune cells, and the hormone appears to have genuine anti-inflammatory properties. In macrophages, ANP reduced the release of tumor necrosis factor alpha (TNF-alpha) and interleukin 1-beta, two of the body’s main inflammation-promoting signals, without affecting anti-inflammatory signals like interleukin 10.14PubMed Central. The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages The same dampening effect held up in whole human blood samples, suggesting it’s not just a lab curiosity. Separately, ANP has been shown to protect lung blood vessel barriers and reduce inflammation in lung tissue, independent of its fluid-regulation role.15European Respiratory Journal. Microtubules mediate anti-inflammatory and lung vascular barrier protective effects of atrial natriuretic peptide
This anti-inflammatory dimension raises the question of whether low ANP activity contributes to the chronic inflammation seen in conditions like heart failure and obesity. Research in this area is still early, but it hints that ANP may do more than just manage plumbing; it may help keep the immune system from overreacting.
Metabolic Effects and Fat Browning
One of the more surprising discoveries about ANP is its influence on fat tissue. The body has two main types of fat: white fat, which stores energy, and brown fat, which burns energy to generate heat. ANP can push white fat cells to take on brown-fat-like characteristics, a process called “browning.” In mice, ANP treatment increased the expression of a key heat-generating protein (UCP1) in white fat depots, effectively turning some storage fat into calorie-burning fat.16Scientific Reports. Treatment with atrial natriuretic peptide induces adipose tissue browning and exerts thermogenic actions in vivo This effect was seen in animals on both normal and high-fat diets, though the response in brown fat itself was muted in the high-fat group.
This connection between a heart hormone and metabolism helps explain an epidemiological puzzle: people with higher natriuretic peptide levels tend to have lower rates of obesity and diabetes, while obese individuals often have unusually low circulating ANP. Whether boosting ANP could meaningfully affect body weight in humans remains an open question, but the biology supporting a link is real.
ANP’s Daily Rhythm
ANP levels in your blood are not constant. They follow a circadian rhythm, peaking at roughly 4:00 a.m. and reaching their lowest point in the afternoon. In both people with normal blood pressure and those with hypertension, this rhythm has been confirmed statistically, and the ANP peak tends to occur in antiphase with blood pressure and heart rate, meaning ANP is highest when blood pressure and heart rate are lowest.17PubMed. Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjects
Body position and meals also influence ANP output. Lying down during the day causes a two- to threefold increase in urinary ANP, because the supine position redistributes blood toward the heart, stretching the atria. Eating increases ANP excretion as well, while fluid intake paradoxically lowers its urinary concentration, likely through a dilution effect.18PubMed. Food intake and body positional change alter the circadian rhythm of atrial natriuretic peptides excretion into human urine These patterns matter for interpreting blood tests: an ANP measurement taken at 8:00 a.m. may look quite different from one taken at 3:00 p.m., even in the same patient.
When ANP Stops Working in Heart Failure
People with advanced heart failure often have extremely high levels of ANP in their blood, yet they remain bloated with fluid and their blood pressure stays elevated. This paradox, sometimes called natriuretic peptide resistance, is one of the hallmarks of severe heart failure. The body is screaming “get rid of fluid” through ANP, but the target organs aren’t listening.
Part of the problem appears to be a dramatic reduction in the activity of ANP’s main receptor, NPRA. In failing hearts, responses to ANP dropped sharply compared to healthy tissue, while responses mediated by a different receptor (NPR-B) were relatively preserved.19Endocrinology. Differential Regulation of Membrane Guanylyl Cyclases in Congestive Heart Failure: Natriuretic Peptide Receptor (NPR)-B, Not NPR-A, Is the Predominant Natriuretic Peptide Receptor in the Failing Heart At the kidney level, the cGMP response to ANP in isolated filtering units fell by as much as 72–96% in experimental heart failure, accompanied by increased activity of enzymes that destroy cGMP.20PubMed. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure So even with plenty of ANP in the blood, the intracellular signal it depends on can’t build up to effective levels.
This resistance helps explain why simply having elevated ANP doesn’t protect patients with severe heart failure. The system is overwhelmed at every level: receptors are downregulated, the signaling molecule is being chewed up too fast, and the kidneys have shifted into a salt-retaining mode that ANP alone can no longer override.
ANP as a Diagnostic Marker
Because ANP rises when the heart is under strain, measuring it (or its more stable fragments) in the blood can help doctors evaluate whether a patient’s shortness of breath is caused by heart failure or something else. The fragment most commonly tested is mid-regional pro-ANP (MR-proANP), a chunk of the precursor molecule that lasts longer in the bloodstream than ANP itself.
In studies of patients who showed up breathless, MR-proANP performed about as well as the more widely used NT-proBNP test. One study found both markers had areas under the receiver operating characteristic curve of 0.92, meaning they distinguished heart failure from other causes of breathlessness with the same high accuracy. MR-proANP also added useful information when NT-proBNP fell into an ambiguous “grey zone” between clearly normal and clearly abnormal.21PubMed. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure That diagnostic accuracy held up across subgroups that often make heart failure testing tricky, including older patients, those with kidney dysfunction, obesity, and atrial fibrillation.22PubMed Central. Comparative accuracy of NT-proBNP and MR-proANP for the diagnosis of acute heart failure in dyspnoeic patients
MR-proANP has also proven useful as a rule-out test. Among outpatients with type 2 diabetes, a low MR-proANP level (below 60 pmol/L) ruled out heart failure with reduced pumping ability with high sensitivity, meaning very few true cases were missed.23PubMed. Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes For clinicians, having a second reliable biomarker alongside BNP/NT-proBNP provides a useful cross-check, especially in patients whose BNP values are hard to interpret.
ANP-Boosting Drugs
The most direct pharmaceutical approach to harnessing ANP’s protective effects came with the development of sacubitril/valsartan (sold as Entresto), a combination drug used in heart failure. Sacubitril inhibits neprilysin, the enzyme that normally breaks down ANP and other natriuretic peptides. By blocking that enzyme, the drug lets ANP accumulate in the bloodstream rather than being rapidly degraded.
In patients with heart failure and reduced pumping ability, starting sacubitril/valsartan produced a rapid rise in circulating ANP, from about 99 pg/ml at baseline to 156 pg/ml within two weeks, with ANP roughly doubling overall at its peak.24PubMed. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients whose ANP rose the most in those early weeks went on to show the biggest improvements in heart pumping function and reductions in the size of the left atrium. A separate analysis confirmed that ANP more than doubled after starting the drug and that the increase was sustained, not a temporary spike.25PubMed. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays
This pharmacological strategy essentially works with the body’s own ANP system rather than replacing it. Instead of injecting synthetic ANP (which has a very short half-life and requires intravenous delivery), the drug prevents the destruction of ANP that the patient’s own heart is already producing. Animal studies have independently shown that intact ANP signaling reduces cardiac fibrosis, preserves pumping function, and improves survival in models of dilated cardiomyopathy, reinforcing the idea that supporting native ANP is genuinely protective.26PubMed Central. Atrial natriuretic peptide affects cardiac remodeling, function, heart failure, and survival in a mouse model of dilated cardiomyopathy
Genetic Variations That Alter ANP’s Impact
Not everyone’s ANP system works equally well, and part of the variation is genetic. In people with essential hypertension, certain variants in the ANP gene have been linked to measurably larger hearts. Patients carrying a specific promoter variant had a left ventricular mass index of about 117 g compared to roughly 96 g in those with the normal version of the gene, along with thicker heart walls. Those same carriers had lower circulating levels of the ANP precursor, suggesting the variant impairs the gene’s ability to produce enough hormone.27Journal of the American College of Cardiology. Association of Atrial Natriuretic Peptide and Type A Natriuretic Peptide Receptor Gene Polymorphisms With Left Ventricular Mass in Human Essential Hypertension These associations held even in patients who had never been treated for high blood pressure, ruling out medication as a confounding factor.
Other genetic analyses have found links between insertion/deletion polymorphisms in the ANP gene and hypertension risk, though results vary by population and by whether diabetes is also present.28PubMed Central. Genetic Analysis of the Atrial Natriuretic Peptide Gene Polymorphisms among Essential Hypertensive Patients in Malaysia The broader point is that genetic differences can leave some people with an underperforming ANP system from birth, which may contribute to their risk of developing high blood pressure and heart enlargement over time.
ANP in Fetal Development
ANP isn’t just a grown-up hormone. It plays a role during fetal development, particularly in the formation of the heart and the regulation of blood flow through the placenta. Peaks in ANP and BNP expression during pregnancy coincide with critical stages of cardiac development, suggesting these peptides help guide how the fetal heart forms. In mice engineered to lack the NPRA receptor, survival was reduced, and hearts were already enlarged at birth, with possible structural abnormalities. The adults that did survive developed high blood pressure and significant cardiac thickening and scarring.29Oxford Academic / Endocrinology. Minireview: Natriuretic Peptides during Development of the Fetal Heart and Circulation These knockout experiments indicate that the ANP signaling system is important not just for day-to-day blood pressure control but for building a properly sized, properly structured heart in the first place.
Evolutionary Origins of the Natriuretic Peptide Family
ANP is a relatively recent addition to an ancient family. Comparative genomic studies suggest that C-type natriuretic peptide (CNP) is the oldest member of the family, found in species as primitive as sharks and lampreys. ANP and BNP appear to have been generated later through gene duplications from one of the ancestral CNP genes.30Comparative Biochemistry and Physiology Part D: Genomics and Proteomics. Molecular evolution of the natriuretic peptide system as revealed by comparative genomics Interestingly, the receptors that respond to natriuretic peptides appear to have evolved before the peptides themselves, at least in vertebrates. Natriuretic-peptide-like molecules found in invertebrates are not true relatives of the vertebrate versions; they arose independently.31PubMed Central. Natriuretic peptides appeared after their receptors in vertebrates
The fact that receptors came first is an unusual evolutionary sequence. It suggests that the receptor machinery was originally serving some other signaling purpose and was later co-opted when natriuretic peptides emerged. For mammals, the key evolutionary innovation was the specialization of ANP for the heart’s atria, creating a dedicated volume-sensing hormone system that supplements the older CNP, which operates more locally in bone, the brain, and blood vessels. That layering of an ancient local system with a newer circulatory one gave mammals a more nuanced toolkit for managing blood pressure across the wide range of body sizes and metabolic demands that mammalian life requires.